Reading GEHC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GEHC free→
GE HealthCare (GEHC)
NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Intact
$63.23-2.36%
Close 2026-06-16 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, but earnings quality is fragile, reported profits aren't backed by cash. Management's recent track record has been fairly steady, though the capital stance is capital unfriendly. The sector backdrop is a headwind, and risk is moderate. Peer multiples imply a price about 40% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while earnings quality is fragile. If GEHC reverses course and raises guidance next quarter, that could signal a sharp positive shift. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Devices
- Market cap
- $29.46B
- Employees
- 54,000
- IPO date
- 2022-12-14
- Next earnings
- 2026-07-29
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 7 valuation methods, at three horizons. Current price $63.23. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$106.03consensus
Range $91.36 – $117.14
vs price: -40% below
Method agreement — · 7 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$148.86consensus
Range $113.05 – $150.78
vs price: -58% below
Method agreement — · 6 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Cheap vs peersmedium confidence
At $65 GEHC trades at 14× p/e, below its 23× p/e peer median. Our $105 fair value sits above the price; medium confidence. Analysts: $65–$90. Not investment advice.
Multiple (P/E)
14.5x
peer 23.0x · own history 16.0x
Premium
0.6x peer
0.9x its own history
Growth the price needs
-38%
our forecast —
Our fair value
$105.08
range $88.03 – $117.64
Analyst range(a guide on our number, not a target)Our number is above the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensivecheap — value-trap risk12-month view
What's priced in
The price sits about 40% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
88th pctl · Health Care
Earnings quality
fragileOver the trailing year it converted 0.28x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
20th pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
neutralEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Neutral14 analysts, 67% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $1.04 → $1.03 (-0.4% / 30d). 0 raised, 14 cut, 14 covering analysts.
Rating actions
1 upgrade, 0 downgrades / 30d, 0 maintained. 67% of analysts rate Buy.
Price target activity
1 PT revisions / 30d. Avg target 7.4% above current price.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: by revenue growth.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- strong
- Post-call reaction
- neutral
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$113.
How much price usually moves either way.
On a bad day, this stock has moved -$330.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,247.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- DownsideHigh confidenceQuartersactive 22d
Watch for Q2 2026 revenue growth below 3.0%
Why it matters: This will indicate if GE HealthCare is struggling to meet its growth targets in a tough market.
What confirms / what disproves
Confirms:Q2 2026 revenue growth reported below 3.0% year over year.
Disproves:Q2 2026 revenue growth reported at or above 3.0% year over year.
Earnings call
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-06-0512d agoYahoo! Finance
Advances: Increase revenue growth
AI oncology push aligns with revenue growth objective.
Strongly reinforcesUnconfirmed report
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If GEHC reverses course and raises guidance next quarter (came in LOWERED as of 2026-04-29), that's a sharp positive shift. The Street usually rewards a 'crisis averted' bounce-back.
- If sector bellwethers like ABT, SYK, and MDT keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting GEHC and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for GEHC and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like ABT, SYK, and MDT start missing or guiding lower, the Healthcare tailwind helping GEHC and other Healthcare names could fade. Watch these names for early warning.
- If GEHC misses again next quarter like this past one (a miss of -6% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-291mo agoItem 2.02
Results of Operations and Financial Condition. On April 29, 2026 , GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2026 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…
Earnings preannouncementneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+3.8 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.